WORLD IMMUNOTHERAPY CONGRESS 2016

14-16 November 2016 | Congress Centre, Basel, Switzerland

DISCOVER. DEVELOP. BRING TO MARKET. FOR BIOTECH, PHARMA AND THEIR PARTNERS.



PARTNERED WITH

Basel

CREATED BY

terrapinn
use your brain

CO-LOCATED WITH

EUROPEAN ANTIBODY CONGRESS 2016

WORLD HPAPI CONGRESS 2016

WORLD BIOSIMILAR CONGRESS EUROPE 2016

For more information please visit **terrapinn.com/immuno2016**

WHAT IS THE WORLD IMMUNOTHERAPY CONGRESS?

Immunotherapy currently offers the brightest hope for cancer treatment. New developments with checkpoint inhibitors and co-stimulatory targets have enabled some stunning breakthroughs and high optimism for the sector. Recently, there have been some incredibly exciting new therapies in areas such as CAR-T and Oncolytic Viral Immunotherapy. Our vision is to bring together the full community and provide a single meeting point for the whole value chain. It is where science meets business to make immunotherapy the cornerstone of the fight against cancer. The event is new, though the ideas and relationships are not. The event comes out of our discussions with leading clinicians, pharmaceutical companies, biotechs and research institutes held every year at successful European Antibody Congress, now in its twelfth successful year.

WHAT'S IN STORE FOR 2016?



Want to get involved? Register online at **terrapinn.com/immuno2016**

Hans-Peter Gerber

Vice President
Pfizer Worldwide Research & Development

Vice President, Pfizer Worldwide Research & Development | Since the acquisition of Wyeth Discover Research Oncology by Pfizer in late 2009, Dr Gerber has been leading the Bioconjugate Discovery and Development group at the Oncology Research Unit in Pearl River, NY. Hans-Peter is building a program to develop novel biotherapeutic drugs, including antibody drug conjugates and bi-specific compounds redirecting immune effector cells to the tumor environment. Dr Gerber is author of more than 90 scientific publications and 10 book chapters, and co-inventor in over 20 issued patents.

Robert Wilkinson

Director of Oncology Research
MedImmune

Dr Wilkinson is charged with the generation and delivery of novel candidate biotherapeutics. His team uses the latest therapeutic strategies (incl. antibody and protein based platforms, oncolytic virotherapy and oligonucleotides) and is focused on immuno-oncology, as well as tumour targeted therapies, such as antibody-drug conjugates (ADCs). Molecules to come out of the group include the GITRL agonist, MEDI1873, and anti-PD-L1 antibody, Durvalumab, which is now in Phase III clinical trials in a range of cancer types. | Previously, Dr Wilkinson has held senior leadership roles with AstraZeneca and Imperial Cancer Research Fund Technology (now Cancer Research Technology. |

Christian Klein

Head of Oncology Programme
Roche

Christian Klein, is Head of Oncology Programs at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development. During his >14 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of GAZYVA/GAZYVARO (obinutuzumab, GA101), the preclinical development of four bispecific antibodies currently in active clinical development: 1) CEA-IL2v immunocytokine RG7813 (Ph I), 2) anti-Ang-2/VEGF CrossMAb RG7221 in oncology (Ph II), 3) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph I) and 4) CEA-CD3 T cell bispecific antibody RG7802 (Ph I), as well as the development of Roche's novel proprietary bispecific antibody platforms e.g. the CrossMAb technology.

Alfred Zippelius

Deputy Head Medical Oncology, Professor of Translational Oncology, **University Hospital Basel**

Alfred Zippelius, MD, is Deputy Head of the Department of Medical Oncology at the University Hospital Basel and is a Professor of Translational Oncology at the Department of Biomedicine, University Basel. Dr. Zippelius' clinical focus is dedicated to the care of patients with lung cancer and advanced melanoma. He is conducting clinical trials as well as supervising clinical and basic research in his laboratory focusing on translational research in the area of cancer immunotherapy with a special focus on T cell directed and combination therapies.

Tariq Ghahur

Senior Principal Scientist and Research Fellow
Abbvie

Tariq Ghayur did his post-doctoral training at McGill (1987-'88) and Dana Farber Cancer Institute (1988-'90). He joined AbbVie Inc. in 1990 and has worked on both small molecule and therapeutic antibody discovery programs. From 1998-2004 he led two therapeutic antibody discovery project teams and delivered 2 drug development candidates. Currently, he leads the dual variable domain Ig (DVD – Ig™) Initiative and the Novel Biologics group at AbbVie.

WORLD IMMUNOTHERAPY CONGRESS 2016

SPOTLIGHT ON SPEAKERS

Renier J. Brentjens

Director of Cellular Therapeutics
Memorial Sloane Kettering Cancer Centre

Dr Renier J. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. Ongoing pre-clinical and clinical research in the focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells."

Steven Lee

Senior Research Fellow, Institute of Immunology and Immunotherapy, **University of Birmingham**

Steven Lee qualified with a PhD at the London School of Hygiene and Tropical Medicine researching immune responses in leprosy patients. He joined the Institute of Cancer Studies at the University of Birmingham where he received a MRC Career Development Award and spent a year working with Profs Phil Greenberg and Stan Riddell at the Fred Hutchinson Cancer Research Centre in Seattle. Steven then obtained a Senior Cancer Research Fellowship from Cancer Research UK to study immune responses to the Epstein-Barr virus (EBV) and EBV-associated human cancers. He now focusses on genetic engineering of T cells to target both virus- and non-virus-associated cancers.

Alfonso Quintas

Global Clinical Leader, Oncology
Novartis

r. Quintas-Cardama is an expert in leukemia who conducted clinical and laboratory-based reasearch at The University of Texas M.D. Anderson Cancer Center. He has published extensively in the subject of drug development in chronic myeloid leukemia, myeloproliferative disorders, acute myeloid leukemia, and myeloid dysplastic syndromes. Currently, he is the Global Clinical Leader for CTL019 in the Cell & Gene Therapies Unit at Novartis AG.

Lindy Durrant

Founder & co-CEO
Scancell

Prof Durrant runs an academic team at the University of Nottingham producing oncolytic monoclonal antibodies for cancer therapy. The most advanced product is in phase II clinical trial in the US for pancreatic cancer. She has over 120 publications and over 50 patents and has significant experience in working with Industry in the commercialization of the technology developed in her research. She is cofounder of and joint CSO of Scancell who developed two cancer vaccine platforms namely ImmunoBody® and moditope® with the most advanced product SCIB1 in phase II clinical trials for the treatment of melanoma.

Patricia Gräf

Associate Scientist Immunology R&D
Juno Therapeutics

Patricia Graef is a research scientist at Juno Therapeutics GmbH with main focus on the processing of T cells for adoptive cellular therapy. Prior to her two years at Juno and former Stage Cell Therapeutics she received her Ph.D. in experimental medicine and immunology from the Technical University of Munich (TUM) for deciphering the stem cell-like properties of T cells. She graduated in Biochemistry with high extinction and was honored from the TUM with the Jürgen Manchot study award.

For speaking opportunities please contact **Joan Shutt** on **+44 (0) 207 002 1134** or email **joan.shutt@terrapinn.com**

WHAT'S INSTORE FOR 2016?

Following your feedback from previous events and in-depth research with your peers, the Congress has been built to solve your daily challenges and provide information on the innovative work in the immunotherapy sector.

EXECUTIVE LEVEL BIG PHARMA AND BIOTECH

With over 30 senior representatives from big pharma and biotechs in the speaker faculty alone, we can guarantee you will have great opportunities to learn from and network with these key stakeholders. Meet C level directors and VPs from Pfizer, Philogen, NBE Therapeutics, MacroGenics, Ossianix, Pieris Pharmaceuticals, Complix, Merck Serono, Cellectis, Immunogen, Replimmune, Humabs, ScanCell, MaxiVax and many more across the event co-location.

EXPERT ACADEMIC AND REGULATORY INDIVIDUALS FROM LEADING INSTITUTIONS

You will hear from Dr Steven Lee (University of Birmingham) on CAR-T and TCRs, Professor Alan Melcher (The Institute of Cancer Research) on Oncolytics, and Professor Alfred Zippelius (University Hospital Basel) on combination therapy. We will also be able to meet with experts from world class establishments including Queen Mary University, University of Surrey, University de Tours, Memorial Sloane Kettering Cancer Centre and European Molecular Biology Laboratory, across the event co-location.

COVERAGE THROUGH MULTIPLE SESSIONS AND EVENTS TO ENSURE THREE DAYS OF RELEVANT CONTENT

The event will feature a Platform Technology Showcase, the Poster Session and two three day tracks across the co-located European Antibody Congress, the World Immunotherapy Congress will ensure that every day is tailored to your needs. Track topics include immune checkpoint innhibitors, cell therapy and novel therapies.

ROUNDTABLE SESSIONS WILL ALLOW YOU TO QUESTION EXPERTS ON KEY TOPICS

With 9 round table sessions run by some of the worlds thought leaders, this will be your opportunity to sit down with an expert in your area to discuss some of the hottest topics in the industry.

MORE NETWORKING OPPORTUNITIES

With three days' worth of content, extended breaks and two drinks receptions, you will have even more time to meet contacts who will progress your projects and offer opportunities for collaboration.

Consisting of high level speakers, involving the whole value chain, the 12th annual European Antibody Congress will look at commercialising and pushing forward the entire developmental pipeline as well as focusing on the hottest new individual therapeutics. Through the last 11 years the event has built up a reputation for delivering high level content and bringing together the senior executives and thought leaders within the space.

EUROPEAN ANTIBODY CONGRESS 2016

Want to get involved? Register online at **terrapinn.com/immuno2016**

DAY 1 – MONDAY 14 NOVEMBER, 2016

08:00 Registration opens

08:55 Conference doors open

09:00 Welcome from Terrapinn
Joan Shutt, Conference Manager, **European Antibody Congress, World Immunotherapy Congress**

Opening Keynotes: New antibody formats and targets

09:15 Chair's opening remarks
Dr Alain Beck, Senior Director CIPF, **Associate Editor, mAbs**

09:45 **Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?**

- Blockade of immune-checkpoints has emerged as one of the most promising approaches to improve the durability of anti-tumour responses in cancer patients
- The fraction of patients experiencing durable responses to single agent immune checkpoint inhibitor treatment remains limited
- Here we review the emerging field of ADC/IO combination research, with a focus on how to optimally combine both modalities

Hans-Peter Gerber, Vice President, **Pfizer Worldwide Research & Development**

10:30 NETWORKING REFRESHMENT BREAK

11:40 **Plenary Round Table Discussion Session**
9 senior level tables hosted by through leaders on key challenges and opportunities in antibody drug development.
Participants are invited to join the group discussions on a topic of importance to them.

TABLE 1
Biomarker annotation – validating laboratory based protocols for GCLP studies
Richard Willock, Senior Director of Business Development, **Asterand**

TABLE 2
Assessing off-target liabilities of biotherapeutics
Jim Freeth, Managing Director, **Retrogenix**

TABLE 3
Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, pAbs
Alain Beck, Senior Director, CIPF, Associate Editors, **mABs**

TABLE 4
Bioanalysis of ADCs
Surinder Kaur, Scientist/Group Leader, **Genentech**

TABLE 5
Therapeutic cancer vaccines – the next generation
Madiha Derouazi, CEO, **Amal Therapeutics**

12:40 SPEED NETWORKING
A fun, exciting and effective way to make a lot of initial connections
(in a very different environment from the standard business networking meetings).

13:00 NETWORKING LUNCH

Want to get involved? Register online at **terrapinn.com/immuno2016**

DAY 1 – MONDAY 14 NOVEMBER, 2016

WORLD IMMUNOTHERAPY CONGRESS 2016

EUROPEAN ANTIBODY CONGRESS 2016

IMMUNE CHECKPOINT INHIBITORS

APPROVED AND MARKETED FORMATS

14:30

Antibody-cytokine fusion proteins (immunocytokines): a novel class of biopharmaceuticals for the treatment of cancer and of chronic inflammatory conditions

- Vascular targeting antibodies in cancer and in non-oncological indications
- Antibody-cytokine fusion proteins for the treatment of chronic inflammation

Dario Neri, Founder, **Philogen**

14:55

Immuno-oncology: current and future advances

- Immuno-oncology (IO) therapies, including checkpoint inhibitors, are demonstrating significant promise in the treatment of cancer. Although these treatments can show significant overall benefit, a subset of patients fails to respond.
- Further advances to the IO field are taking the form of novel immunotherapies aimed at targeting: T-cell effector responses (such as, tumour necrosis factor receptor (TNFR) superfamily agonists); antigen presenting cell (APC) function (such as, toll-like receptor (TLR) agonists and virotherapy); and the elimination of immune suppression pathways.
- Presented are preclinical approaches to develop novel IO agents and examine combination paradigms.

Robert Wilkinson, Director of Oncology Research, **MedImmune**

15:20

How to execute clinical trials in the increasingly competitive realm of immunotherapy drug development

- Understanding of the common core challenges central to complex immunotherapy clinical trials, across indications
- Planning for key considerations common to these trials as well as finding appropriate solutions to proactively address them
- Identifying an experienced CRO partner to help plan for, mitigate and overcome the core challenges to immunotherapy trials of all types

Etienne Drouet, VP Strategic Development**, SynteractHCR**

ARMED ANTIBODIES

Chaired by: **Ulf Grawunder,** CEO, **NBE Therapeutics**

NEXT GENERATION ADCS

Small is beautiful – Humabodies Drug Conjugates, HDC's a real alternative to ADC's

- HDC demonstrate exceptionally fast tumour penetration
- HDC facilitate low systemic exposure
- Humabodies enable plug and play engineering allowing simple exploration of limitless format options
- The versatility of the Humabody™ format enables creation of optimal HDC format and half-life with improved Therapeutic Index

Thomas Sandal, VP of preclinical Development and Protein Engineering, **Crescendo Biologics**

Sortase-mediated antibody conjugation (SMAC-TechnologyTM) for developing homogeneous antibody drug conjugates

- Highly site-specific conjugation yields homogenous drug product with defined efficacy, PK properties and safety profile.
- Novel highly potent payload that allows targeting of tumor specific antigens that cannot be addressed with conventional ADCs.
- Presentation of in vitro and in vivo efficacy data of SMAC-technologyTM-conjugated ADCs currently in pre-clinical development.

Ulf Grawunder, CEO, **NBE Therapeutics**

Brentuximab vedotin: drug loading, aggregation and Fc neonatal receptor binding

- The various drug-to-antibody ratio species of brentuximab vedotin (BTXv) are easily separated by hydrophobic interaction chromatography
- Species with higher drug loading show a higher tendency to aggregate
- Cellular and surface plasmon resonance FcRn binding assays gave consistent results
- FcRn binding assays showed that the most conjugated species, interacted more strongly than unconjugated BTXv with the FcRn at pH6, but not at pH7.4

Guillaume Brachet, Research Pharmacist, **University of Tours**

BISPECIFICS

ENGINEERING BISPECIFICS
BISPECIFIC DEVELOPMENT

Development of anti-CD3 bispecifics for the treatment of haematological malignancies

- Target selection for acute myeloid leukaemia, non-Hodgkin's lymphoma, and multiple myeloma.
- Selection of CD3 arms to match target and optimize therapeutic index
- Pharmacodynamic assessment of activity in non-human primates

Andrew Polson, Principal Scientist, **Genentech**

The DART and Trident multispecific antibody platforms: Applications in oncology, infectious diseases and autoimmunity

- DART® and TridentTM platforms and their applications
- Redirected T-cell killing: models of anti-tumour activity
- Preclinical pharmacology experience in non-human primates
- DART molecule-mediated T-cell killing for HIV eradication
- Exploiting checkpoint inhibition for the treatment of autoimmune diseases

Ezio Bonvini, Senior Vice President of Research, **MacroGenics**

Bispecific T-Cell Engagers (BiTE®) for the Treatment of Malignant Diseases

- Streamlined screening and engineering process
- Beyond BLINCYTO® - updates on clinical development programs
- Challenges of combination therapy with checkpoint inhibitors

Matthias Klinger, Principal Scientists – BiTE Immunology, **Amgen**

15:45

NETWORKING BREAK

16:30

Costimulatory T cell engagement via a novel bispecific anti-CD137/anti-HER2 protein

- We generated four variants of a bispecific protein binding to CD137 and the tumour target HER2
- The bispecifics of this cancer drug program (termed PRS-343) are designed to promote CD137 clustering by bridging T cells with HER2- positive tumour cells, and to thereby provide a potent costimulatory signal to tumour antigen-specific T cells
- We show ex vivo that T cells are efficiently activated when incubated with a bispecific and HER2-positive cells, and that the activation is HER2-dependent. T cells are not activated by a bispecific in the presence of cells that express HER2 at levels that are similar to healthy tissue

Shane Olwill, Vice President Development, **Pieris Pharmaceuticals**

DeBouganin, a de-immunized plant toxin protein, as a rational alternative to small molecule payloads

- In vitro and in vivo comparison of trastuzumab-deBouganin conjugate versus T-DM1
- deBouganin MOA overcomes MDR mechanisms
- deBouganin is cytotoxic against Cancer Stem Cells
- deBouganin is potent against tumor cells surviving one ADC treatment

Jeannick Cizeau, Director of Research, **Viventia**

A bispecific brain penetrant anti CD20(Rituxan) for CNS lymphoma

- CNS Lymphoma is refractory to existing anti CD20 therapy
- A brain penetrant version of anti CD20 (Rituxan) was generated with a VNAR to the transferrin receptor (TfR)
- The bispecific product effectively enters the CNS and retains cytotoxic activity
- This product promises to provide an effective treatment for B cell mediated CNS disease

Frank Walsh, CEO, **Ossianix**

COMBINATION THERAPY | NOVEL BINDING STRATEGIES | BLOOD-BRAIN BARRIER PENETRATING DUAL SPECIFIC BINDING

16:55

Antibody based combination immunotherapy of cancer

- Novel IL2v immunocytokine platform for combination therapy
- Novel T cell bispecifics platform
- PD-L1 combination therapy

Christian Klein, Head of Oncology Programme, **Roche**

Development of novel quaternary ammonium linkers for antibody-drug conjugates

- A quaternary ammonium-based drug-linker has been developed to expand the scope of antibody-drug conjugate (ADC) payloads to include tertiary amines, a functional group commonly present in biologically active compounds
- The drug-linker was found to efficiently release free auristatin E (AE) in the presence of beta-glucuronidase and provide ADCs that were highly stable in plasma
- The quaternary ammonium linker represents a significant advance in linker technology, enabling stable conjugation of payloads with tertiary amine residues.

Patrick Burke, Associate Director, **Seattle Genetics**

Proteins for Treating Brain and Neurological Diseases

- Will describe the generation and expression of DVD-Ig proteins which are capable of binding specific disease targets in the brain.
- The brain uptake and retention, following an systemic administration, as well as the elevated functional activity of DVD-Ig proteins will be demonstrated.

Denise Karaoglu Hanzatian, Principal Research Scientist, **AbbVie Bioresearch Centre**

17:20

Combined treatment with T-DM1 and anti-CTLA-4/PD-1 triggers innate and adaptive immunity in HER2+ breast cancer

- Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy
- We show that T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer

Alfred Zippelius, Deputy Head Medical Oncology, Professor of Translational Oncology, **University Hospital Basel**

Latest advances developing ADCs using SMARTag technology

- Will present novel, innovative approaches to bioconjugation with a focus on ADC applications
- Novel linker design for improved ADC efficacy and tolerability
- Preclinical data packages and data highlighting our CD22 ADC

David Rabuka, Head of Global R&D, Chemical Biology, **Catalent**

High Throughput Binding Assays to Support Bispecific Antibody Discovery

Senior Executive, **PALL ForteBio**

17:45

Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities

- Epidermal growth factor receptor (EGFR) and receptor tyrosine-protein kinase 3 (ErbB3) are two well-established targets in cancer therapy
- To block signalling from both EGFR and ErbB3, we generated anti-EGFR and anti-ErbB3 DVD-Ig protein
- The DVD-Ig proteins inhibit cell signalling and proliferation in A431 and FaDu cells while half DVD-Ig proteins lost proliferation inhibition function

Tariq Ghayur, Senior Principal Scientist and Research Fellow, **AbbVie**

Producing Better ADCs Using ThioBridge™ Conjugation

- Disulfide re-bridging conjugation to reduce ADC heterogeneity
- ThioBridge™ linkers provide stable conjugation
- PK profiles of ThioBridge™ ADCs vs maleimide conjugation
- Development of more efficacious ADCs

George Badescu, Director of Scientific Affairs, **Abzena**

mAb platform processes - quo vadis?

- The journey of mAb process platforms, from their initial development and application to the present day with its focus on next generation platforms and platforms for novel mAb related molecules.
- The development and key attributes of this platform that combines speed of development with robustness, scalability and cost-effectiveness
- Contrast the approach taken at KBI with other high column loading downstream platform alternatives for example ones that rely exclusively on the use of flow-through mode polishing steps
- The KBI mAb process platform approach has enabled the progression of several mAbs from gene to IND in less than a year

Abhinav Shukla, Senior VP, Process Development & Manufacturing, **KBI Biopharma Inc.**

18:10 Chair's closing remarks

18:15 NETWORKING DRINKS RECEPTION

DAY 2 – TUESDAY 15 NOVEMBER, 2016

WORLD IMMUNOTHERAPY CONGRESS 2016

EUROPEAN ANTIBODY CONGRESS 2016

	CELL THERAPY	EARLY DISCOVERY AND ANALYTICS	BISPECIFICS
	CHAIR: **Alfonso Quintas,** Global Clinical Leader, Oncology, **NovartisNBE Therapeutics**	RECAP OF DAY 1 AND CHAIR'S OPENING REMARKS FOR DAY 2	RECAP OF DAY 1 AND CHAIR'S OPENING REMARKS FOR DAY 2
9:00	RECAP OF DAY 1 AND CHAIR'S OPENING REMARKS FOR DAY 2		
9:10	ANTIGEN TARGETS	NOVEL SCREENING STRATEGIES	**Empowering a commercial anti-TNFa antibody through fusion with a potent anti-IL-23 Alphabody: the development of the Bispecific Therapeutic CMX04** • Rationale and design options • Anti-TFNa and anti-IL-23 potency • Manufacturing, serum stability, solubility at high concentrations • Pharmacodynamics **Ignace Lasters,** CTO, **Complix**
	CAR T cell therapy for Cancer: We have a Model A Ford, we need to build a Ferrari • Define the concept of CAR T cell therapy for cancer. • Recognise barriers to CAR T cell therapy of cancer including T cell persistence, antigen escape, and the immune suppressive tumor microenvironment. • Recognise novel CAR T cell designs utilized to optimize anti-cancer efficacy of this novel approach as well as how these armored CAR T cell designs may bridge the gap from liquid to solid tumor **Renier J. Brentjens,** Director of Cellular Therapeutics, **Memorial Sloane Kettering Cancer Centre**	**Insights of multilevel state-of-the art analytical methods for antibody-based product structural assessment** • Emerging 2D-LC-MS methods for mAbs and ADCs • Orthogonal chromatographic and electrophoretic methods hyphenated to Mass Spec • FDA/EMA approved mAbs and ADCs case studies **Alain Beck,** Senior Director, CIPF, Associate Editor, **mABs**	
		New classes of ADCs and new methods for generating and screening these • An overview of the numerous ADCs Immunogen currently have on development • Methods Immunogen are developing to screen for these antibodies • Future uses for the technology in development **Nicholas Yoder,** Scientist III, **Immunogen**	**An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants** • The controlled Fab-arm exchange (cFAE) method combines two parental monoclonal antibodies (mAbs), each with a matched point mutation, F405L and K409R in the respective CH3 domains • The BsAbs generated had efficiency comparable to the conventional method using purified parental mAbs • This alternative method significantly shortened timelines and reduced resources required for bsAb generation, providing an improved process with potential benefits in large-scale bsAb preparation, as well as for HTP small-scale bsAb matrix selection. **Haiyan Jiang,** Principal Scientist, Biotechnology Centre of Excellence, **Janssen R&D**
10:00	**CTL cell therapy in haematological malignancies** • Current status of clinical trials • Clinical outcomes with CAR T cell therapy across different indications • CAR T cell toxicity and its management **Alfonso Quintas,** Global Clinical Leader, Oncology, **Novartis**	**Living droplets – functional screening of murine and human plasma cells at very high throughput** • Droplet based microfluidics for the direct screening of millions of primary murine (from spleen and bone marrow) and human (from blood) plasma cells. • Assays for antibody binding, inhibition of enzymatic drug targets, effect on target cells. • Compatible with difficult targets such as GPCRs. **Christoph Merten,** Principal Investigator, Genome Biology Unit, **European Molecular Biology Laboratory**	**Bispecific FynomAbs for T-cell redirection. Novel modes of action through tailored architecture** • Fynomers are small binding proteins that can be selected from large combinatorial libraries to bind almost any target antigen of choice • Fynomers can be attached to all ends of an antibody resulting in bispecific FynomAbs with tailored architectures and activities • We have created bispecific anti CD3 FynomAbs that induce T-cell redirected tumor cell killing with pM potency. • Bispecific CD3-FynomAbs could therefore improve the safety of T-Cell redirecting molecules and increase the therapeutic window. **Ulrich Wuellner,** Associate Director, Discovery Research, **Covagen AG**
10:25	NETWORKING BREAK		

WORLD IMMUNOTHERAPY CONGRESS 2016

EUROPEAN ANTIBODY CONGRESS 2016

	ANTIGEN TARGETS	TARGET DISCOVERY	CMC AND DEVELOPABILITY
11:25	**Effective immunotherapy using CAR T cells** • Update on most recent work done within CAR T cells • New data on new formats and targets **Patricia Gräf,** Associate Scientist Immunology R&D, **Juno Therapeutics**	**In silico methods for antibody discovery** • The BIOS group is developing innovative bioinformatics method to facilitate the development of therapeutics antibodies that allow to: • Predict the epitope of an antibody • From an initial antibody, find other antibodies with same target • Find cross-reactive targets for an antibody **Anne Poupon,** CNRS/INRA, **University de Tours**	**Advancements and pitfalls in single use based operations and plant design** • Single use implementation in different fed-batch plant set-ups • Impact of vendor dependencies and pitfall potential • Validation efforts single use versus hard-piped • Continuous processing and single use **Berthold Boedeker,** Chief Scientist, Global Biologics Development, **Bayer Pharma AG**
11:50	CELLULAR THERAPY FOR SOLID TUMOURS **Targeting the tumour vasculature with chimeric antigen receptor (CAR)-expressing T cells** • Characterising a tumour endothelial marker highly expressed in a wide variety of human solid tumours • Engineering T cells to express a chimeric antigen receptor specific for this vascular target • In vitro and in vivo studies exploring the safety and efficacy of this approach **Steven Lee,** Senior Research Fellow, Institute of Immunology and Immunotherapy, **University of Birmingham**	**Uncovering critical receptor targets and off-target binding using plasma membrane protein array technology Case studies will describe:** • A powerful approach to identify specific receptors for phenotypic antibodies and immune checkpoint ligands • Efficient off-target profiling of biotherapeutics including antibodies, ADCs, scFvs and whole CAR T cells **Elizabeth Kingsley,** PR & Marketing, **Retrogenix**	
12:15		ADC BIOANALYTICS **Living droplets – functional screening of murine and human plasma cells at very high throughput** • Droplet based microfluidics for the direct screening of millions of primary murine (from spleen and bone marrow) and human (from blood) plasma cells. • Assays for antibody binding, inhibition of enzymatic drug targets, effect on target cells. • Compatible with difficult targets such as GPCRs. **Christoph Merten,** Principal Investigator, Genome Biology Unit, **European Molecular Biology Laboratory**	**Gene to cGMP: Efficient strategies to deliver reliable, high quality biomanufacturing processes** • How Fujifilm Diosynth Biotechnologies' cell line development and upstream process development platforms were modified and optimized to develop customized reliable manufacturing processes. • Development of the Apollo™ Mammalian Expression Platform • Establishment of a "tool box" strategy targeting media, feeds, and process conditions to achieve desired cell culture performance • Upfront development of a robust single-use process platform to streamline manufacturing operations and provide advantages in technology transfer **Fay Saunders,** Senior Staff Scientist, **Fujifilm Diosynth Biotechnologies UK**
12:40	NETWORKING LUNCH		
14:20	ALLOGENEIC CELL THERAPY **Collaboration to utilize Cellectis' proprietary allogeneic CAR-T platform technology to develop immunotherapies against select targets in the field of oncology** • Development and commercialization of CAR-T therapies, in the field of oncology, directed at a total of fifteen targets • Work together on preclinical research on four Cellectis-selected targets and Cellectis will work independently on eight additional targets • leading immuno-oncology collaboration aimed at delivering immunotherapies is built upon Cellectis' advanced genome editing and cell engineering capability and Pfizer's cutting-edge biotherapeutic cancer therapy platform **Phillipe Duchateau,** Chief Scientific Officer, **Cellectis**	**Label-free methods for characterizing the binding interactions of antibodies with the neonatal Fc receptor (FcRn)** • FcRn plays a central role in extending an antibody's serum half-life, yet published studies on the molecular binding mechanism of the FcRn/IgG interaction have been confounded by an earlier hypothesis of disparate FcRn-binding sites. • Combining the use of optimized label-free biosensor methods and our bispecific antibody technology, we demonstrate that two FcRn molecules bind an IgG homodimer with identical affinities at independent sites. • We present a detailed set of affinities for a multi-species panel of FcRn/IgG interactions that can be used for future measurement comparison. • Our in vivo studies highlight the biological importance of avidity in extending an IgG's serum half-life. **Yasmina Abdiche,** Research Fellow, Head of Bioanalytics Group at Rinat-ORRD, **Pfizer**	CONTINUOUS PROCESSING **Are >10'000-L stainless steel bioreactors obsolete?** • Are the > 10,000-L stainless steel bioreactors the best choice for implementing additional manufacturing capacity for biologics? • New approaches and technologies for reaching high performance processes. • How to manage speed to first-in-man and development of high performance processes? • Combining Process-of-the-Future and Facility-of-the-Future. **Herve Broly,** Vice President Biotech Process Development, **Merck Serono SA**

DAY 2 – TUESDAY 15 NOVEMBER, 2016

WORLD IMMUNOTHERAPY CONGRESS 2016

EUROPEAN ANTIBODY CONGRESS 2016

14:45

CLINICAL AND PRE-CLINICAL DEVELOPMENT

ImmTACs: novel bi-functional TCR-based biologics for targeted immunotherapy

- ImmTACs target tumors via a soluble monocloncal TCR with exceptionally high sensitivity and specificity and redirect host polyclonal T cells via an anti-CD3 antibody fragment
- As ImmTACs are specific for humans efficacy, specificity and off target effects are assessed in an in vitro preclinical package using antigen positive tumor cells and HLA appropriate primary human cell lines representing a range of tissues
- First in human studies with the lead ImmTAC, IMCgp100, show a favourable safety profile and promising signs of durable efficacy in both cutaneous and uveal melanoma

Bent Jakobsen, Chief Scientific Officer, **Immunocore**

Quantitative analysis of maytansinoid (DM1) in human serum

- Method was developed and validated for the quantitation of maytansinoid (DM1) in human serum using on-line solid phase extraction (SPE)-liquid chromatography-tandem mass spectrometry (LC-MS/MS)
- DM1-NEM exhibited sufficiently stability under all relevant analytical conditions and no DM1 losses from the ADC were observed
- The assay was used for DM1 determination in human serum concentration after the intravenous administration of an investigational antibody drug conjugate (ADC) containing DM1 as payload

Olivier Heudi, Laboratory Head, **Novartis Pharma AG**

15:10

Updates and movements within Cancer Research and next steps

- A brief overview of the diverse range of Phase I biological and immunological therapies within the CRUK CDD portfolio
- Discuss the trial designs and non-clinical strategies employed to successfully translate some of these therapies into early clinical development

David Edwards, Preclinical Scientist, **Cancer Research UK**

LIBRARY DEVELOPMENT

Ribosome and Phage Display for Rapid Cell-free Antibody Engineering

- Cell-free (CF) protein synthesis platform for rapidly expressing IgGs
- Custom ribosome and phage display antibody libraries which allow simultaneous screening of 100s of IgGs using CF
- Novel, high-affinity antibodies containing non-natural amino acids can then be scaled using CF for making potent, site-specific ADCs

Ryan Stafford, Associate Director, Protein Engineering, **Sutro Biopharma**

15:35

NETWORKING BREAK

Regulation and Intellectual Property

16:30

Antibody nomenclature

- Overview of the new definitions for the assignment of antibody international non-proprietary names (INN) made by the World Health Organisation (WHO) in 2014
- The new definitions suffer from several major limitations that make them unworkable
- A discussion about the naming of antibodies and how this can be made to work for you

Robin Thorpe, Head of Bio therapeutics, **National Institute of Biological Standards and Control**

16:55

Update on Patenting Antibodies and related technologies at the EPO

- Abs defined by reference to the epitope only
- Abs defined by functional features only
- Comparative data should be comparable

Helena Domingues, Examiner, Joint Cluster Biotechnology, Immunology Directorate, **European Patent Office**

17:20

POSTER SESSION

Informal, interactive presentation and discussion of diverse topics in the field of antibody discovery, development, manufacture and trials. Authors are invited to submit proposals relating to innovative projects, best practices and original research findings. Refreshments will be served throughout.

NETWORKING DRINKS RECEPTION

DAY 3 – WEDNESDAY 16 NOVEMBER, 2016

08:00 Registration opens

WORLD IMMUNOTHERAPY CONGRESS 2016 | EUROPEAN ANTIBODY CONGRESS 2016

	NOVEL THERAPIES	CLINICAL AND PRE-CLINICAL DEVELOPMENT	FUTURE USES FOR ANTIBODIES
9:00	RECAP OF DAY 2 AND CHAIR'S OPENING REMARKS FOR DAY 3	RECAP OF DAY 2 AND CHAIR'S OPENING REMARKS FOR DAY 3	RECAP OF DAY 2 AND CHAIR'S OPENING REMARKS FOR DAY 3
9:10	ONCOLYTICS **Using oncolytics in the CANON trial for bladder cancer, and combining this with immune checkpoint antibodies** • Overview of the current work being carried out on the CANON trial, using Oncolytic viruses to treat bladder cancer • Discussion of the mechanisms behind the therapy • Where can oncolytics take us next? **Hardev Pandah,** Professor of Medical Oncology, **University of Surrey**	**Integrating ADC Design and Clinical Development** • ADCs offers a strategy for developing anti-cancer drugs of great promise • In creating effective, well-tolerated, ADCs, each of the elements in their design, from target selection, selection of the antibody, the cytotoxic "payload", and the linker, are important. • These elements will be illustrated with examples from ImmunoGen's clinical pipeline. **John Lambert,** CSO & Executive VP, **Immunogen**	**Targeting therapeutic and regenerative biomedicine specifically for arthritic joints** • An overview of antibody use in non-typical therapeutic areas • The work being done currently using regenerative antibodies for arthritis • Where we can take antibodies next, away from oncology **Ahuva Nissim,** Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology, **William Harvey Research Institute, Queen Mary University**
9:35	**Developing the next generation of Oncolytic immunotherapy** • Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time inducing a potent, patient-specific, anti-tumor immune response • Oncolytic viruses have the unique ability to generate an autologous immune response to the patient's particular complement of tumor antigens, including neoantigens, with a truly off-the-shelf approach • Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-**tumor** effects of selective virus replication and the potency of the immune response to the tumor antigens released **Colin Love,** Chief Operations Officer, **Replimune**	**The clinical progress on SGN-CD33A, SGN-CD19A and SEA-CD40** • Updates and new data on Seattle Genetics' new formats • Coverage on the three formats currently in clinical trial • Data and next steps for these trials **Nancy Whiting,** Vice President, Head of Medical Affairs, **Seattle Genetics**	**Blockade of cytokines/cytokine networks in autoimmunity and transplantation** • Simultaneous targeting of multiple cytokines and pathways by monoclonal antibodies • Blockade of common gamma chain cytokines to disrupt crosstalk between innate and adaptive immunity • Surrogate antibodies in pre-clinical studies for proof-of-mechanism and therapeutic efficacy • Phamacodynamic and functional assays to predict dosing and efficacy **Jiri Kovarik,** Senior Research Investigator, **Novartis Institutes for Biomedical Research**
10:00	**Oncolytic viruses as Immunotherapy – from Laboratory to Clinic** • Although oncolytic viruses were initially developed as direct cytotoxic agents, increasing evidence has shown that they act more by stimulating anti-tumour immunity i.e. they are a type of immunotherapy • The first oncolytic virus, T-Vec, a herpes virus encoding GMCSF, has been approved for clinical use in advanced melanoma, administered by intratumoural injection • Systemic, intravenous delivery of viruses would pave the way for more widespread clinical application • Biological endpoint, translational clinical trials, have shown that systemic administration can deliver viruses to tumours and initiate an immune response **Alan Melcher,** Professor of Translational Immunotherapy, **The Institute of Cancer Research**	**Brain shuttle platform to open the blood brain barrier gate for biologics** • Blood brain barrier the challenges for CNS drug delivery • Brain delivery of biotherapeutics • The pRED Roche Brain Shuttle Programme **Eduard Urich,** Senior Scientist, **Roche** Awaiting final confirmation	**Antibodies harvested from Ebola survivors stop symptoms five days after infection** • Antibodies harvested from an Ebola survivor 11 years after the 1995 Kikwit outbreak in the Democratic Republic of Congo mAb100 and mAb114 • Macaques tested with the antibodies did not experience any Ebola symptoms • The antibody could be an effective treatment for those who contract Ebola, even in later stages • Second study looked at how the structure of the two different antibodies interacted with the virus **Davide Corti,** Senior Vice President and Chief Scientific Officer, **Humabs**
10:25	NETWORKING DRINKS RECEPTION		

DAY 3 – WEDNESDAY 16 NOVEMBER, 2016

WORLD IMMUNOTHERAPY CONGRESS 2016

EUROPEAN ANTIBODY CONGRESS 2016

11:25

CANCER VACCINES

SCIB1, SCIB2 and moditope novel cancer vaccines

- SCIB1 causes regression of stage IV melanoma and is shortly to enter combination trials with PD.1 blockade
- SCIB1 induces remarkable survival in fully resected stage III/IV melanoma with some patients remaining disease free for 4 years
- SCIb2 is a new vaccine for NCSCLC
- Moditope is a novel vaccine that shows how CD4 cells can mediate potent antitumor responses against modified self- epitopes presented on tumour cells, and they illustrate for the first time how the citrullinated peptides may offer especially attractive vaccine targets for cancer therapy

Lindy Durrant, Founder & co-CEO, **Scancell**

Continuous antibody delivery using encapsulated cell technology (ECT): prevention of Alzheimer's disease and beyond

- Encapsulated cell technology : the concept
- Anti-amyloid beta antibody delivery using ECT for the prevention of Alzheimer's disease, a proof of concept study
- ECT application in cancer immunotherapy
- Perspectives

Aurélien Lathuilière, Scientific Resident, **Hôpitaux Universitaires de Genève**

True Human™ antibodies

- Until now each and every therapeutic antibody on the market has been derived through gene sequence modification in the laboratory to produce the desired antibody product.
- Marketed antibodies to date, described as "fully human", and are not derived from human gene sequences that have undergone the crucial process of selection in a human.
- XBiotech's lead product Xilonix™ is expected to be the only product to be marketed that is a true human antibody.

Michael Stecher, Medical Director, **XBiotech**

12:15

Development of MVX-ONCO-1 and clinical trial data

- Using both the patient's own irradiated cancer cells as vaccine agents and an immune boosting agent, GM-CSF, delivered in a proprietary manner via sustained release from encapsulated cells
- MaxiVAX has now successfully completed a first-in-man Phase I clinical study, and is now planning to perform several Phase II multicentre clinical studies, in different types of cancer

Nicolas Mach, Chief Scientific Officer, **Maxivax**

Crossing the cell membrane barrier

- Alternative protein scaffold using consensus based approach to make scaffold
- Aiming to allow proteins to target within the cytosol
- Do not use anchor particles of anchor protein placement

Wouter Verdurmen, Researcher, Department of Biochemistry, **Radboudumc**

12:30

NETWORKING LUNCH

Closing Plenary: The future of antibodies and immunotherapy

14:00

Immune modulation – Targeting beyond the CTLA-4/PD-1 axes

- Blockade of CTLA-4 (approval of ipilimumab in unresectable or metastatic melanoma in 2011) opened the doors for immunotherapy
- PD-1 pathway therapies demonstrated higher response rates across multiple indications with improved safety profile
- Combination therapy: rapid and durable responses with anti-PD-1 and anti-CTLA-4 combination. However, responses rates remain insufficient with the majority of patients not responding or relapsing and multiple "cold" tumors that do not response to checkpoint blockade. Strategic use of combinations will expand the responding patient populations and improve immunologic memory, and therefore durable responses
- Combinations may require targeting the suppressive tumor microenvironment; priming an anti-tumor response through strategies such as vaccines; checkpoint blockade; and combination with established standard of care/targeted therapy

Catherine Sabatos-Peyton, Senior Scientist II, **Novartis**

14:25

Antibodies to watch in 2017

- A new record for recombinant antibody products granted first marketing approvals is likely to be set in 2016. These products, and those that might be granted approvals in 2017, will be identified.
- Antibody therapeutics in Phase 3 clinical studies will be discussed, and the question of which are likely to move to regulatory review in 2017 will be explored.
- So far, few 'next generation' formats such as antibody-drug conjugates and multi-specific antibodies have progressed to late-stage clinical studies. The current commercial pipeline of these promising formats will be assessed.

Janice Reichert, Executive Director, **The Antibody Society**

14:50

THANK YOU & CLOSING REMARKS BY TERRAPINN

15:00

END OF CONGRESS

Want to get involved? Register online at **terrapinn.com/immuno2016**

CO-LOCATED WITH

For three days, the global biologics community descends on Basel. With the co-location of three fantastic events – the European Antibody Congress, the World Biosimilars Congress and the HPAPI World Congress – comes over 140 world-leading speakers and hundreds of brand new case studies explored.

14th November

WORLD IMMUNOTHERAPY CONGRESS 2016

Immune Checkpoint Inhibitors

- Approved Market Formats
- New Agents
- Combination Agents

Co-Stimulatory Targets

- New Developments Formats and Receptors

EUROPEAN ANTIBODY CONGRESS 2016

- Putting antibody development into the wider healthcare context
- Antibody-drug conjugates
- Target discover and computational biology
- Bispecific antibodies

WORLD BIOSIMILAR CONGRESS EUROPE 2016

- Healthcare impact – What is the demand? Where is demand greatest?
- Exploring priorities – Impact of healthcare cost and number of patients treated
- Healthcare uptake Clinicians and pharmacies discuss prescription concerns
- Reimbursement and payer response

15th November

WORLD IMMUNOTHERAPY CONGRESS 2016

Cell Therapy

- Antigen Targets
- Cell Therapy for solid tumours
- Allogeneic gene therapy

EUROPEAN ANTIBODY CONGRESS 2016

- Protein engineering
- Protein expression
- Analytics
- Immunogenicity and bioanalytics
- Immunotherapies

WORLD BIOSIMILAR CONGRESS EUROPE 2016

- Regulation and market access
- Clinical development
- Interchangeability and extrapolation
- Analytics and comparison to originator products

16th November

WORLD IMMUNOTHERAPY CONGRESS 2016

Novel Therapies

- Oncolytic viral immunotherapies
- Vaccines

EUROPEAN ANTIBODY CONGRESS 2016

- Platform technology showcase
- Clinical development
- CMC and developability
- Bioprocessing and production

WORLD HPAPI CONGRESS 2016

- Handling and containment
- Processing
- Exposure risk mitigation
- Monitoring

SPOTLIGHT ON SESSIONS

IMMUNE CHECKPOINT INHIBITORS

Focusing on the next generation of cancer application and autoimmune disease therapies, we will look at the discovery and development of many antibody based immunotherapies, covering novel and newly marketed formats, formats designed for co-stimulatory targets, and combination therapy of T cells and antibodies.

Robert Wilkinson
Director of Oncology Research, **MedImmune**
"Immuno-oncology: current and future advances"

Christian Klein
Head of Oncology Programme, **Roche** *"Antibody based combination immunotherapy of cancer"*

CELL THERAPY

From huge recent advances in CAR-T therapy and TCR, cell therapy looks to be the focus of day two, where we will set out to discuss the concept of CAR T cell therapy for cancer and the barriers to CAR T cell therapy of cancer, CTL cell therapy in haematological malignancies, cellular therapies for solid tumours and allogeneic cell therapies.

Renier Brentjens
Director of Cellular Therapeutics, **Memorial Sloane Kettering Cancer Centre**
"CAR T cell therapy for Cancer: We have a Model A Ford, we need to build a Ferrari"

Alfonso Quintas
Global Clinical Leader, Oncology, **Novartis**
"CTL cell therapy in haematological malignancies"

REGULATION AND INTELLECTUAL PROPERTY

From International Non-proprietary Names (INN) of antibodies, to patenting antibodies, this session look to cover issues that attendees may be having with the new naming system of antibodies, ensuring that your antibody obtains it patent, and other related issues within regulation and intellectual property.

Robin Thorpe
Head of Biotherapeutics
NIBSC *"Antibody Nomenclature"*

Helena Domingues
Examiner, Joint ClusterBiotechnology, Immunology Directorate, **European Patent Office** *"Update on Patenting Antibodies and related technologies at the EPO"*

NOVEL THERAPIES

As the immunotherapy industry garners increasing interest from the pharmaceutical and biotechnology industries, more and more research are being carried out in areas such as Oncolytics and Cancer Vaccines. On day three we will hear from a number of industry experts in this field, where they will reveal new data and progression within these new research areas within immunotherapy.

Alan Melcher
Professor of Translational Immunotherapy, **The Institute of Cancer Research**
"Oncolytic viruses as immunotherapy – from laboratory to clinic"

Lindy Durrant
Founder & co-CEO, **ScanCell**
"SCIB1, SCIB2 and moditope novel cancer vaccines"

Want to get involved? Register online at **terrapinn.com/immuno2016**

10 REASONS TO ATTEND

1. Hear opening keynotes from industry leaders Pfizer Worldwide Research & Development, where they will talk about combining antibody technology with immunotherapy
2. Learn about the newest CAR-T and TCR developments from leading industry experts from Novartis, Juno Therapeutics and Cellectis to name a few.
3. Get involved in one of our 9 round table discussions with industry leading experts such as Alain Beck, Associate Director of mAbs, and Surinder Kaur from Genentech.
4. Be the first to hear from top level pharma and biotech insiders from Pfizer, Philogen, MedImmune, Replimune, Scancell and Maxivax.
5. Hear from Dr Renier Brentjens, Director of Cell Therapy at Memorial Sloane Kettering define the concept of CAR T cell therapy for cancer, and explain how armored CAR T cell designs may bridge the gap from liquid to solid tumor treatment.
6. Meet and engage with over 500+ key decision makers in the numerous networking sessions across the event, including a dedicated poster session where you can discuss new findings with top scientists.
7. Hear new, not yet published data from important establishments such as University Hospital Basel, The Institute of Cancer Research, University of Surrey, Cancer Research UK and University of Birmingham.
8. Last year, our extensive exhibition area saw over 30 companies demonstrating their new products and exciting technological advancements which could benefit many areas of your business. Meet with all of them and more at our event this year. Additionally, we have the Platform Technology Showcase where companies with brand new technology will be demonstrating and talking about their new products.
9. Hear from the leading Professor Alfred Zippelius talk about combined treatment for ADCs and immune checkpoint inhibitors, and how this is particularly effective in eliciting anti-tumour immunity in certain cancer patients.
10. With the co-located European Antibody Congress, the World Biosimilar Congress and the HPAPI World Congress, there will be over 500+ industry professionals to rub shoulders with, and with two drinks receptions and numerous networking breaks there will be plenty of opportunity to meet with people who have the capability to improve your business.

Want to get involved? Register online at **terrapinn.com/immuno2016**

TESTIMONIALS

"The conference is very focused on subjects of interest to me and my colleagues"

GROUP LEADER & HEAD OF MOLECULAR BIOLOGY EXPERTISE, **MERCK-SERONO,** EUROPEAN ANTIBODY CONGRESS 2015

"Very good event in terms of quality of talks, participants and networking time"

KEY ACCOUNT MANAGER, **QUALITY ASSISTANCE S.A. ,** EUROPEAN ANTIBODY CONGRESS 2015

"Excellent Networking"

PROFESSOR OF BIOCHEMICAL ENGINEERING, **VIENNA UNIVERSITY OF TECHNOLOGY,** DOWNSTREAM PROCESSING WORLD CONGRESS 2016

"The talks were very interesting"

HEAD OF US DRUG SUBSTANCE TECHNICAL DEVELOPMENT, **NOVARTIS VACCINES AND DIAGNOSITCS,** CELL CULTURE WORLD CONGRESS 2015

"This is THE Cell Culture World event, where you discuss about novelties, meet the most important players, and learn about the offer on the market."

GLOBAL TECH TRANSFER MANAGER, **SANDOZ BIOPHARMACEUTICALS,** CELL CULTURE WORLD CONGRESS 2015

"It was a very specialized exhibition and it was very well sorted and arranged."

HEAD PRODUCT SPECIALIST, **ABBOTT GMBH & CO.,** CELL CULTURE WORLD CONGRESS 2015

"Good congress to catch up with main issues related to development of biosimilars"

SENIOR PROJECT MANAGER, **MERCK GROUP,** WORLD BIOSIMILAR CONGRESS 2015

"I found this conference very useful in terms of the presented topics and networking opportunities"

SENIOR DIRECTOR BUSINESS DEVELOPMENT, **QUINTILES GMBH,** WORLD BIOSIMILAR CONGRESS 2015

"Very well integrated program with good presentations and networking activities. Very well organized"

VICE PRESIDENT, **PAREXEL,** WORLD BIOSIMILAR CONGRESS 2015

"This is an excellent strategic conference on the global development of biosimilars and should be attended by anyone developing biosimilars."

SENIOR CONSULTANT, **NDA REGULATORY SCIENCE,** WORLD BIOSIMILAR CONGRESS 2015

"Excellent meeting, great content and the speakers were fantastic."

FOUNDER AND EXECUTIVE DIRECTOR, **SAVE THE CORD FOUNDATION,** CORD BLOOD WORLD EUROPE 2015

"The event was a great mixture of academic and applied industry session along with updates and insights into clinical trials and policy."

DIRECTOR, VACCINE PROCESS DEVELOPMENT, **MERCK,** WORLD VACCINE CONGRESS WASHINGTON 2015

"A very well-organised conference with plenty of networking opportunities during the day and in the evening, and very interesting presentations and panel discussions from experts in several areas of vaccine development."

CHIEF SCIENTIFIC OFFICER, **PROJARIUM LTD,** WORLD VACCINE CONGRESS WASHINGTON 2015

"The networking was fantastic for my agency--Vaccinate One World. I found new grant opportunities, I networked regarding global issues and I won an iPad from one of the exhibitors."

ADMINISTRATOR IF HEALTH SERVICES, **VACCINATE ONE WORLD,** WORLD VACCINE CONGRESS WASHINGTON 2015

"Great wmeeting"

PROFESSOR OF LEUKOCYTE AND STEM CELL BIOLOGY, **IMPERIAL COLLEGE LONDON,** STEM CELL AND REGENERATIVE MEDICINE CONGRESS 2015

Want to get involved? Register online at **terrapinn.com/immuno2016**

THE EXHIBITION

WHO ATTENDS:

- Heads of Pharma
- Heads of Biotech
  - Heads of governmental and regulatory
  - Research / Academia
  - Healthcare
  - Associations
  - Patient Groups

4A	Reserved
7	Reserved
8	Retrogenix
9	CMC Biologics
10	Agilent Technologies
11	KBI Biopharma
13	Pall Life Sciences
15	PhyNexus, Inc.
17	Aldevron
18	Quality Assistance
22	DEC

24	Carbogen Amcis
26	Reserved
28	Synteract HCR
28A	2AbD Serotec, a Bio-Rad Company
29	DiscoverX
29A	Asterand Bioscience
30	Avacta
31	Bucher Biotec/ Intellicyt
33	FPS
34	Fujifilm Diosynth
37	Bio-techne



WHO SPONSORS:

PLATFORM| TECHNOLOGY

CMO

CRO

EQM

CELL LINE| DEVELOPERS

UPSTREAM /| DOWNSTREAM

REGULATORY AND| BUSINESS STRATEGY CONSULTANTS

BIO-INFORMATICS | AND COMPUTATIONAL| BIOLOGY

LAW FIRMS

NON-GOVERNMENTAL| ORGANISATIONS

WORLD IMMUNOTHERAPY CONGRESS 2016

To learn more about how to exhibit, sponsor or speak at this year's event call **Derek Cavanagh** on **+44 (0)20 7092 1297** or email **derek.cavanagh@terrapinn.com**

SPONSORSHIP AND EXHIBITION PACKAGES

BENEFITS	PLATINUM	GOLD	SILVER	EXHIBITION	PLATFORM TECH PACKAGE
Keynote Plenary Presentation or Interview	1				
Track Presentation	1	1			
Roundtable Host	2	1	1		
On-Floor Demonstration	2	1	1		
Access to Networking Manager	Up to 12 meetings	Up to 8 meetings	Up to 5 meetings		
Lead generation services	2 emails	1 email	Newsletter		
Delegate passes	6	3	2	Added on request	1
Exhibition booth	24 sqm	12 sqm	9 sqm	Purchased by sqm – 6 up to 24	
Platform tech pitch					1

EUROPEAN ANTIBODY CONGRESS 2016
Derek Cavanagh
+44 207 092 1297
derek.cavanagh@terrapinn.com

WORLD IMMUNOTHERAPY CONGRESS 2016
Derek Cavanagh
+44 207 092 1297
derek.cavanagh@terrapinn.com

WORLD BIOSIMILAR CONGRESS EUROPE 2016
Toby Lomax
+44 207 092 1249
toby.lomax@terrapinn.com

WORLD HPAPI CONGRESS 2016
Toby Lomax
+44 207 092 1249
toby.lomax@terrapinn.com

IT'S A NETWORKING EVENT

The World Immunotherapy Congress recognizes the importance of networking and offers an experience which allows you to do just that.

ROUNDTABLE DISCUSSIONS

With moderators to lead discussions on key topics, you will take your engagement and learnings to a new level in this interactive and results-driven setting.

NETWORKING RECEPTION

It's not always about the conference sessions. Our themed evening networking drinks receptions both at the conference venue and off-site on days one and two will allow you to unwind with your peers and continue conversations in good company.

SCIENTIFIC POSTERS

Share research with leaders in the antibody sector within the dedicated Scientific Poster session. Posters allow for pharma, biotech and academia to present previously unpublished work. Taking place before the networking drinks on day two of the congress, it will be possible for poster contributors to answer questions and gain feedback. Refreshments will be served throughout. | Please see **terrapinn.com/immuno2016** for further details.

NETWORKING LUNCHES

Our extended lunch periods will provide you with ample time to network between sessions. These lunch formats allow for more opportunities for casual conversations and introductions, without compromising your time attending the conference sessions.

WHO ATTENDS ?

Over 500 delegates will be attending this year's co-located event from pharma, biotech, clinicians, academics, researchers and start-ups.

Although this is the launch of the World Immunotherapy Congress, check out all the companies who attended the co-located Antibody combo last year:

3M (Schweiz) GmbH | 4-Antibody AG | A Generics Company | A.I.B.N. The University of Queensland | AbbVie | AbbVie Bioresearch Center Inc | Abcam | AbCellera | AbD Serotec, a Bio-Rad Company | Ablynx | Abmart | Absave | Abzena | Actelion Pharmaceuticals Ltd | Adaptimmune Ltd | ADC Therapeutics | Agenesys/Astellas | AGES Austrian Medicines and Medical Devices Agency | Agilent | Technologies | Agilent Technologies (Schweiz) AG | Agilent Technologies Denmark A/S | Albany Molecular Research Inc | Aldevron Llc | Alliance Boots Holdings 1 Ltd. | Alliance for Safe Biologic Medicines | Almirall | Ambios Ltd | Amgen | Amgen Research Munich Gmbh | Amring | Amunix Inc | Anabiotec | Antibody Engineering Macrogenics | Aptuit Srl | Arsanis Inc | Asebio Spanish Bioindustry Association | Asterand Bioscience | Asterand U.K. | AstraZeneca | AstraZeneca Global | Atlab Pharma | Atlantica Hotels | Aurealis Pharma | Avacta Life Sciences | Avicenna Oncology GmbH | Axon Lab Ag | Azienda Ospedaliera Papa Giovanni XXIII, Bergamo | Banco Nacional De Desenvolvimento Economico E Social | Barts Health NHS Trust | Basilea Pharmaceutica International Ltd. | Bayer HealthCare | Bayer Pharma AG | Bayer | Technology Services GmbH TD-DP-SP | Bentham Science Publishers | Bio Rad | bioeq | BIOLOTUS BIOTECH | BIOMUNEX PHARMACEUTICALS | BioPharmaSpec Ltd | BioProcess International | Bioprocessing Technology Institute | Biosave | Biotechpharma U.A.B. | Bispebjerg Hospital | Blood Transfusion Centre of Slovenia | Boehringer Ingelheim Pharma GmbH & o. KG | Bonetti & Partner GmbH & Bonetti Biotech | Bucher Biotec AG | Buhlmann Laboratories Ag | Calibr - California Institute for Biomedical Research | Cancer Research UK | Cantargia AB | Canton of Basel-Stadt | Caprion | Carbogen Amcis AG | Carbogen Amcis Switzerland | Catalent | Catalent Pharma Solutions | CDER, FDA | Cellestia Biotech | Celltrion | Celonic A.G. | Centre d'Immunologie Pierre Fabre | ChargePoint Technology Ltd | Chemical Company of Malaysia Berhad | ChemPartner | Chiome Bioscience, Inc. | Cinfa Biotech | Cirion Clinical Trials Inc. | Clean Cells | Comecer | COMECER GROUP | Compugen Ltd | Cook Pharmica | Covagen AG | Creoptix AG | Crescendo Biologics Ltd | CRT | CSBJ journal | Cytune Pharma SAS | DiscoveRx | Corporation | DPS Engineering | Drugdesigntech SA | Elanco c/o Novartis Animal Health Inc | Eli Lilly and Company | Epirus Biopharma | Epirus Biopharmaceuticals | ESBATech, a Novartis company | Eurogentec | EuropaBio | European Molecular Biology | Laboratory | European Patent Office | Express Scripts | F. Hoffmann-La Roche Ag | F. Hoffmann-La Roche Ltd | F.Hoffmann-La Roche | F.P.S. Food and Pharma Systems | F.P.S. Food and Pharma Systems Srl | FairJourney Biologics | FAREVA | Ferring International SA | Fraunhofer Gesellschaft | Fraunhofer Institute of Cell Theraphy & Immunology | Fujifilm Diosynth Biotechnologies | Fujifilm Kyowa Kirin Biologics | G.T.P. Technology | GaBI Journal - Generics and Biosimilars Initiative Journal | Gen9 Inc | Genentech | Genetika | Genmab | Genovis | Genovis AB | Genzyme | Genzyme AS | Glatt Gmbh | GlaxoSmithKline | Glenmark Pharmaceuticals | Global Colon Cancer Association | Harvard School of Public Health | Health Canada | Health Products Regulatory | Authority, Ireland | Heyl Chem.-pharm. Fabrik GmbH & Co.KG | Horiba | Horiba Jobin Yvon Sas | Hospira | HPC Pharma | Humabs BioMed Sa | Ibis Technologies | Ibis Technologies BV | Icosagen Cell Factory OÜ | iDD Biotech | Immatics Biotechnologies GmbH | Immune Deficiency Foundation | Immunocore Ltd | ImmunoGen | ImmunoGen Inc | IMS Health | In-Cell-Art | Incubizz | Indraprastha Apollo Hospitals | I-Net | Infa Group | INFA SA | Innate Pharma | Inofea Gmbh | INSERM | Inserm Transfert | Institut Pluridisciplinaire Hubert Curien | Intellicyt Corp | Iptechex Pharmalicensing | ITALFARMACO S.P.A. | ITRI | Janssen Research and Development Llc | JETPHARMA SA | Johnson & Johnson | Johnson Matthey | K.B.I. Biopharma | Kadmon Corporation | Karolinska Institutet | KBI Biopharma Inc. | Keires | L.F.B. Biomanufacturing M.A.B. Launch | Labochim – Infa Group | Labsave | LEGER Consulting | Lek Pharmaceutical | LFB Biomanufacturing (MAbLaunch) | LFB Biotechnologies | Life Science Connect | Linxis | Lonza | Lonza AG | Lonza Inc | Luminex | Luminex Bv | MabDesign | Maschio & Soames IP Limited | Maschio and Soames IP | Medical News Today | Medichem SA | MedImmune | Medimmune Inc | Mega Lifesciences Pty Ltd | Memorial Sloan Kettering | Menarini Biotech S.R.L. | Merck | Merck Chemicals GmbH | Merck Group | Merck Group GmbH | Merck Serono | Merck Serono S.A. | Merck-Serono (InterLab) | Merrimack Pharmaceuticals | Merus B.V. | Micro-Macinazione SA | Minakem | MorphoSys AG | MRC Technology | MSPharma | Myoderm | N.B.E. Therapeutics Llc | N.D.A. Regulatory Science Ltd | N.I.B.R. | NanoTemper | NBE Therapeutics | NDA Advisory Services Ltd | NDA Group | Neurimmune Therapeutics AG | NNE Pharmaplan | Northern Biologics Inc. | Novartis | Novartis Ag | Novartis Pharma AG | Office of Economy and Labour, Economic Development | OGD2 Pharma | One Nucleus | ORIL | Oril Industrie | Ossianix, Inc. | Oxford BioTherapeutics Ltd | P. J. Safarik University - School of Medicine | Pall Corporation | Pall Life Sciences | Pall Schweiz | PAREXEL | Patients for Biologics and safety & Access rational 360 | Pfizer | Pfizer Worldwide Research and Development. | Pfizer, Inc | pharmaphorum | Pharmascience Inc | PharmaZell GmbH | Piramal Healthcare | Prescient Healthcare Group | Private Group Practice | Process Service | Procos S.p.A. | Promega Corporation | Quality Assistance S.A. | Quintiles GmbH | RADS | R-Biopharm Rhone Ltd | Reichert Biotechnology Consulting Llc | Reithera | Retrogenix | Roche | Roche Diagnostics | Roche Diagnostics GmbH | Roche Glycart AG | Roche Innovation Center Basel | Roche Innovation Center Zurich | Roche NimbleGen Inc | Roche Pharmaceutical Research and Early Development | Roche Pharmaceuticals | RQM Consulting | Russell Publishing Ltd | SafeBridge Europe | SafeBridge Europe Ltd | SAI | Sanofi | Sanoma | Sanora Bio | Sanovo Biotech | Sanquin | Sartorius Stedim Biotech GmbH | Seattle Genetics Inc | SelectScience | Servier | SGS-MScan SA | Sigma-Aldrich | Silapakorn University, Faculty of Pharmacy | Skan A.G. | Solvias Ag | Solvinax | Start-up Business Department | Stemcentrx Inc | Sterne Kessler Goldstein And Fox Plc | Swiss Biotech Association | Swiss Federal Institute of Technology Zurich | Sycomore Technologies | SymCel AB | Symcel Sverige AB | Synthon Biopharmaceuticals BV | Taylor & Francis Group Ltd | Technology Networks | Tg Therapeutics, Inc. | Thai FDA | Thai Food and Drug Administration | The Ella Lemelbaum Institute of Melanoma, Sheba Medical Center | The Hematology/Oncology Pharmacy Association | Thermo Fisher Scientific | Total Biopharma | TTP Labtech | TWC Pharma Consulting GmbH | Twist Bioscience Corp. | UCB | Umicore AG & Co. KG | United Spinal Association | Univ Washington Seattle | University Hospital Basel | University of Arizona College of Pharmacy | University of Birmingham | University of Nantes | University of Oslo | University of Southampton | University of Zurich | VTT Technical Research Centre Of Finland | William Harvey Research Institute Queen Mary University of London | WS Biologics Consulting UG | Wyatt Technology Europe | XL Services Switzerland Ltd |

REGISTER YOUR PLACE TODAY



The earlier you book the more you'll save.
terrapinn.com/immuno2016

Package	Before 15 Apr 16	Before 27 May 16	Before 26 Aug 16	Before 16 Sep 16	Before 07 Oct 16	Before 28 Oct 16	Final Price
Standard Package	£1,620 **SAVE £1350**	£1,890 **SAVE £1080**	£2,160 **SAVE £810**	£2,430 **SAVE £540**	£2,565 **SAVE £405**	£2,700 **SAVE £270**	£2,970
Academic & Regulatory Package	£810 **SAVE £675**	£970 **SAVE £515**	£1,080 **SAVE £405**	£1,215 **SAVE £270**	£1,285 **SAVE £200**	£1,350 **SAVE £135**	£1,485
Display a Scientific Poster	£50	£50	£50	£50	£50	£50	£50
3-5 people Standard Package	£1,700	£1,945	£2,190	£2,310	£2,430	£2,675	
3-5 people Academic & Regulatory Package	£875	£970	£1,095	£1,160	£1,215	£1,335	

BOOK NOW

Register at
terrapinn.com/immuno2016
Or call **+44 (0) 207 092 1257**

BRING YOUR TEAM

With three days packed full of great content and networking opportunities, you can't possibly cover it all alone!

Bring your team and get an extra discount.

Call **+44 (0) 207 092 1257**

2016 SPONSORS & EXHIBITORS

RETROGENIX™ SPOTTING YOUR TARGET.

CMC biologics Right. On Time.

Agilent Technologies

KBI BIOPHARMA

PALL Life Sciences

PhyNexus

aldevron

QUALITY ASSISTANCE Contract Research Organisation

CARBOGEN AMCIS A Dishman Group Company

SynteractHCR

AbD Serotec® A Bio-Rad Company

DiscoverX

ASTERAND BIOSCIENCE EXPERTS IN HUMAN TISSUE

Dec Group

Avacta GROUP PLC

FPS FOOD PHARMA SYSTEMS

FUJIFILM Diosynth biotechnologies

biotechne

nano TEMPER technologies

LFB BIOTECHNOLOGIES

ABZENA Enabling better biopharmaceuticals

Catalent BIOLOGICS

bucher biotec

intellicyt

Media Partners

biosave Exceptional Savings for Life Scientists

BENTHAM SCIENCE

ANTIBODY SOCIETY

SWISS BIOTECH

TECHNOLOGY NETWORKS

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL

MEDtube sharing medical knowledge™

total biopharma

The Cell Culture Dish

inet

iptechex pharmalicensing

For sponsorship and exhibition opportunities, please contact **Derek Cavanagh**
t/ **+44 (0) 207 092 1297** e/ **derek.cavanagh@terrapinn.com**